Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > COIN Hosts Risk vs. Reward: Financing Early-Stage, Emerging Technologies NanoBio Executive Roundtable

Abstract:
The Center of Innovation for Nanobiotechnology (COIN) has announced the upcoming NanoBio Executive Roundtable event to be hosted at The Hawthorne Inn in Winston-Salem, NC on July 14, 2011. This Roundtable will address a significant hurdle to nanobiotechnology development and commercialization—early-stage funding. The "Risk vs. Reward: Financing Early-Stage, Emerging Technologies" brings together a panel of seasoned investors and entrepreneurs to discuss the risk involved in investing in early-stage platform nanobiotechnologies. The panelists will also discuss how entrepreneurs in this space can more effectively approach the appropriate investors to accelerate commercialization.

COIN Hosts Risk vs. Reward: Financing Early-Stage, Emerging Technologies NanoBio Executive Roundtable

Durham, NC | Posted on June 30th, 2011

The expert panelists include Scott Albert, a former Venture Partner with Aurora Funds and now with Centice, who just announced a $2.3m round of funding. Christy Shaffer, a former CEO of Inspire Pharmaceuticals and recently joined as a Venture Partner and Managing Director at Hatteras Venture Partners, an early stage fund for life sciences. Steven Walsh, an experienced serial entrepreneur at the University of New Mexico and founder of MANCEF. Mr. Walsh has raised over $200m for several nanotechnology related ventures in recent years. This panel will be moderated by Andy Dreyfuss, a Fund Executive at the Winston Salem based Piedmont Angel Network, who has invested in nanotechnology companies like Protochips.

This NanoBio Executive Roundtable event series offers executives and entrepreneurs of North Carolina-based nanobiotechnology companies and others involved in this exciting field an opportunity to discuss key business issues and build relationships. In total, the previous four Roundtables have attracted over 500 attendees from eight states. "The COIN Roundtable events provide unique opportunities to meet and interact with the movers and shakers of Nanobiotech in NC...an event you can't miss" -Anil Goyal, President, CEO, Qualiber Inc.

COIN coordinates these Roundtables to stimulate dialogue in the community and be a catalyst for relationship-building that is critical for accelerating the commercialization of nanobiotechnology. COIN is a non-profit that is a single point of entry into the nanobiotech community and offers high-value programs and services that are designed to help accelerate innovation management and new product development and commercialization in the area of nanobiotechnology and nanomedicine.

Risk vs. Reward: Financing Early-Stage, Emerging Technologies is a key topic of discussion for the growing nanobiotechnology sector. COIN has invited these experts to discuss the critical issue of funding for emerging technologies. Without appropriate early-stage funding that allows continued development , many promising emerging technologies are at risk of running out of resources. The NanoBio Executive Roundtable event will be held at the Hawthorne Inn (420 High Street, Winston-Salem, NC) on July 14, 2011 from 5:30 to 7:30 pm, with registration opening at 5 pm. Attendees will also enjoy a gala networking reception that facilitates connections that lead to collaborations and new business relationships. There are several generous sponsors for the NanoBio Executive Roundtable series, including RTI International, McDonnell Boehnen Hulbert & Berghoff LLP (MBHB), MEMSCAP, and Grant Thornton. Prasidiux has generously sponsored the networking reception at this Risk vs. Reward: Financing Early-Stage, Emerging Technologies event and RTI International sponsored speaker travel.

To register for this free event, please visit riskvsrewardjuly.eventbrite.com/.

####

About The Center of Innovation for Nanobiotechnology (COIN)
COIN is a nonprofit organization that accelerates commercialization of nanobiotechnology and nanomedicine to enable economic growth and improve human life. North Carolina is a leader in these fields and in related new product innovation and entrepreneurship. Established with funding from the NC Biotechnology Center, COIN represents a targeted state resource to encourage development of commercial applications of nanobiotechnology in key life science and medical product sectors. COIN provides a framework to boost the profile, funding, and management of the important work occurring in nanobiotechnology in the state, with the ultimate goal being commercialization. COIN’s programs and services address key issues of its clients such as early-stage funding, preclinical testing, technology scouting, and industry partnering.

For more information, please click here

Contacts:
Dr. Laura Faulconer
Director, Innovation Projects
The Venable Center
303 South Roxboro St., Suite 30
Durham, NC 27701

Office: (919) 680-2070 ext 301

Copyright © The Center of Innovation for Nanobiotechnology (COIN)

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Events/Classes

A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024

Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023

CEA & Partners Present ‘Powerful Step Towards Industrialization’ Of Linear Si Quantum Dot Arrays Using FDSOI Material at VLSI Symposium: Invited paper reports 3-step characterization chain and resulting methodologies and metrics that accelerate learning, provide data on device pe June 17th, 2022

June Conference in Grenoble, France, to Explore Pathways to 6G Applications, Including ‘Internet of Senses’, Sustainability, Extended Reality & Digital Twin of Physical World: Organized by CEA-Leti, the Joint EuCNC and 6G Summit Sees Telecom Sector as an ‘Enabler for a Sustainabl June 1st, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project